NCT01069913View on ClinicalTrials.gov

Pharmacokinetics Profile Study of BG00012 Standard Formulation and BG00012 Active Pharmaceutical Ingredient

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 31, 2009

Primary Completion Date

October 31, 2009

Study Completion Date

January 31, 2010

Conditions

Healthy

Interventions

DRUG

BG00012

"Sequence 1: Oral 240 mg BG00012 Standard Formulation \& Following 7 day washout period, 240 mg BG00012 API.~Sequence 2: 240 mg BG00012 API \& Following 7 day washout period, 240 mg BG00012 Standard Formulation."